Recursion is scheduled to report its first quarter 2025 financial results, providing transparency and updates to investors, which can enhance trust and investor relations. The company'searnings ...

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...